Funded by the Spanish Association Against Cancer (AECC) and coordinated by IDIBAPS and the Salamanca Cancer Research Centre, ASPIRE-AECC aims to impr1
The IDIBAPS researcher Josep M. Llovet has participated in the new American AASLD guidelines for the treatment of hepatocellular carcinoma, the most1
Researchers at the Hospital Clínic-IDIBAPS and the University of Barcelona have published a review article in the journal Nature Cancer in which they1
Immunotherapy has revolutionized the treatment of hepatocellular carcinoma. Researchers from the Hospital Clínic-IDIBAPS have published a review in t1
Researchers at IDIBAPS have led a study, published in the journal Gastroenterology, in which they analyzed the clinical trials published in the past1
IDIBAPS researchers have drafted a molecular map of the most common type of liver cancer, hepatocellular carcinoma, when the origin is fatty liver di1
An article published in the journal Nature suggests that immunotherapy is effective in patients with HCC of viral origin but does not increase surviv1
Clínic-IDIBAPS researchers have coordinated two review articles on hepatocellular carcinoma (HCC), the most common type of liver cancer, in which the1
